1. Home
  2. KFY vs MIRM Comparison

KFY vs MIRM Comparison

Compare KFY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KFY
  • MIRM
  • Stock Information
  • Founded
  • KFY 1969
  • MIRM 2018
  • Country
  • KFY United States
  • MIRM United States
  • Employees
  • KFY N/A
  • MIRM N/A
  • Industry
  • KFY Diversified Commercial Services
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • KFY Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • KFY Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • KFY 3.9B
  • MIRM 3.3B
  • IPO Year
  • KFY 1999
  • MIRM 2019
  • Fundamental
  • Price
  • KFY $72.46
  • MIRM $67.93
  • Analyst Decision
  • KFY Buy
  • MIRM Strong Buy
  • Analyst Count
  • KFY 2
  • MIRM 9
  • Target Price
  • KFY $80.00
  • MIRM $73.89
  • AVG Volume (30 Days)
  • KFY 257.6K
  • MIRM 661.2K
  • Earning Date
  • KFY 09-04-2025
  • MIRM 08-06-2025
  • Dividend Yield
  • KFY 2.62%
  • MIRM N/A
  • EPS Growth
  • KFY 42.44
  • MIRM N/A
  • EPS
  • KFY 4.60
  • MIRM N/A
  • Revenue
  • KFY $2,730,088,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • KFY $3.15
  • MIRM $36.76
  • Revenue Next Year
  • KFY $4.79
  • MIRM $17.48
  • P/E Ratio
  • KFY $15.93
  • MIRM N/A
  • Revenue Growth
  • KFY N/A
  • MIRM 62.33
  • 52 Week Low
  • KFY $59.23
  • MIRM $36.86
  • 52 Week High
  • KFY $80.64
  • MIRM $69.00
  • Technical
  • Relative Strength Index (RSI)
  • KFY 51.91
  • MIRM 82.95
  • Support Level
  • KFY $70.18
  • MIRM $50.25
  • Resistance Level
  • KFY $74.54
  • MIRM $67.45
  • Average True Range (ATR)
  • KFY 1.33
  • MIRM 2.89
  • MACD
  • KFY 0.18
  • MIRM 1.38
  • Stochastic Oscillator
  • KFY 64.08
  • MIRM 94.29

About KFY Korn Ferry

Korn Ferry is a United States-based firm engaged in organizational consulting and management recruitment that helps clients fill mid- to high-level management positions. The company's segment includes Consulting; Digital; Executive Search; Professional Search & Interim; and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The consulting segment aligns organizational structure, culture, performance, development, and people to drive sustainable growth by addressing four fundamental organizational and talent needs. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: